knowledge -WSS

knowledge

author：Wikipedia 2025-10-02 18:06:12 - browse：562

Dr. Peter Marks, Director of the Center for Biologics Evaluation and Research within the Food and Drug Administration, at a hearing — policy coverage from STAT — Peter Marks, director of the FDA's Center for Biologics Evaluation and Research Greg Nash/Pool via AP

WASHINGTON — A top Food and Drug Administration official wants Congress to dedicate full-time staff to emerging pathogens, after the FDA scrambled to find people for Covid-19 priorities like Operation Warp Speed.

“Vaccines were a pretty heavy duty lift during the pandemic,” said Peter Marks, director of the Center for Biologics Evaluation and Research, at a Thursday Politico event. “Rather than having to essentially reassign whole groups of people and disrupt things, the idea is to have a group of people who are constantly working on this.”

There is reason for optimism. Sens. John Hickenlooper (D-Colo.) and Ted Budd (R-N.C.) successfully added an amendment creating that team to a key pandemic preparedness bill that must be reauthorized by the end of September. It would establish this new program within Marks’ division of the FDA, staffed with experts on vaccines, antibodies, diagnostic tests, personal protective equipment, and other medical countermeasures. Among other activities, this team would enhance surveillance programs and prioritize vaccine research and development so that existing platforms can be retooled to fight other viruses.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

WSS

Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

Researchers tackle phage therapy hurdles for wider adoption

Bipartisan group of lawmakers warns of a rising Chinese threat to U.S. biotech

Kenai launches with $82 million for Parkinson’s stem cell therapy

International team creates first chimeric human

Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

focus

knowledge

focus

The cancer drug shortage isn’t new — and neither are the solutions

Opioid cravings were reduced by anti

Anesthesiologist group: stop taking Ozempic before surgery

Kenai launches with $82 million for Parkinson’s stem cell therapy

Peter Hotez and the public health issue of online harassment

RSV vaccines may be linked to small increased risk of developing GBS

The high cost of giving birth even with insurance

Ring Therapeutics, a Flagship gene therapy startup, lays off 20% of staff

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Kristina Burow of ARCH Venture Partners shares her next big bets STAT

focus

Flagship Pioneering startup Sonata Therapeutics lays off 21

RaDonda Vaught to speak at CommonSpirit event on patient safety

Weight loss drugs aren’t covered by Obamacare. That may change

ALS groups 'won't be played again' by the FDA, drug sponsors

Abortion pill mifepristone to soon be dispensed at CVS, Walgreens

MD Anderson's Padmanee Sharma responds to research credit suit

focus

hotspot

hotspot

hotspot